Impact of Moderate to Severe Renal Impairment on Mortality and Appropriate Shocks in Patients with Implantable Cardioverter Defibrillators

Table 1

Baseline characteristics of the study population.

	GFR ≥ 60	GFR 30–59	GFR < 30	P-value
	(𝑛 = 289)	(𝑛 = 188)	(𝑛 = 32)
Age (years)	68	69	73	.04
Male Gender (%)	92	88	83	.10
DM	32	36	40	.08
Hypertension	71	78	82	.9
NYHA class ≥ 3 (%)	51	63	71	.04
QRS > 120 msec (%)	30	49	54	.40
Ejection Fraction (mean)	32	32	28	.60
Ischemic heart disease	77	83	89	.04
BUN (mean)	20	34	48	<.03
Creatinine (mean)	1.0	1.4	1.8	<.01
Hemoglobin (mean)	14.0	13	12.6	.06
Indication:Primary Prevention (%)	72	76	84	.08
𝛽 blocker (%)	74	78	78	.97
ACEi (%)	63	58	54	.28
ARB (%)	14	22	21	.28
Aldosterone inhibitor (%)	6	8	9	.39
Digoxin (%)	52	50	51	.85
Loop diuretic (%)	48	64	68	.03
Statin (%)	69	64	60	.29
Anti-arrhythmic (%)	19	28	32	.44

DM: diabetes mellitus; BUN: blood urea Nitrogen; ACEi: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; NYHA: New York heart association; Statin: hydroxyl-methyl-glutaryl CoA inhibitors.